SCHEDULE: Samsara BioCapital Acquires 9.9% Stake in PMV Pharmaceuticals

Samsara BioCapital, through affiliated funds and individuals, has reported beneficial ownership of 9.9% of PMV Pharmaceuticals' common stock, following a recent equity offering.

Summary

• Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, Samsara Opportunity Fund, L.P., Samsara Opportunity Fund GP, LLC, and Srinivas Akkaraju (collectively, the 'Reporting Persons') have filed a Schedule 13G.
• The filing indicates beneficial ownership of 7,577,467 shares of PMV Pharmaceuticals, Inc. common stock, representing 9.9% of the class.
• This ownership level is a result of recent equity transactions, including a public offering that closed on September 2, 2026.
• The Reporting Persons have stated they do not form a 'group' for the purposes of this filing.
• Beneficial ownership includes shares and warrants, with 'Beneficial Ownership Blockers' in the warrants limiting exercise to prevent ownership exceeding 9.99%.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but not controlling stake acquisition by Samsara BioCapital, which could signal confidence in PMV Pharmaceuticals' future prospects.

Positives

• Samsara BioCapital has taken a significant stake (9.9%) in PMV Pharmaceuticals, which can be interpreted as a vote of confidence in the company's potential.
• The acquisition of shares and warrants suggests an active investment strategy by Samsara BioCapital.
• The company has recently completed a public offering, indicating ongoing capital market activity and potential for growth funding.

Negatives

• The 'Beneficial Ownership Blockers' in the warrants limit the ability of Samsara BioCapital to increase its stake beyond 9.99% through warrant exercise, capping potential influence.
• The filing is a Schedule 13G, indicating passive investment, rather than a Schedule 13D, which would suggest a more active or controlling interest.

Risks

• The 'Beneficial Ownership Blockers' in the warrants may limit the Reporting Persons' ability to exercise their full rights or influence the company if their ownership approaches 9.99%.
• The passive nature of the filing (Schedule 13G) suggests that the Reporting Persons are not actively seeking to control or influence the company's management or operations, which may limit their impact on strategic decisions.
• Future market performance of PMV Pharmaceuticals' stock will be subject to the company's operational success and broader market conditions.

Future Outlook

The filing itself does not contain forward-looking statements or specific guidance from PMV Pharmaceuticals. The future outlook for the company is dependent on its business operations and market performance, with Samsara BioCapital's significant stake potentially indicating a positive view on its prospects.

Management Comments

• The Reporting Persons expressly disclaim status as a 'group' for purposes of this Schedule 13G.
• By virtue of the Beneficial Ownership Blocker, each of Samsara LP and Samsara Opportunity Fund is currently prohibited from exercising the Warrants to the extent that such exercise would result in the Reporting Persons' beneficial ownership of more than 7,577,467 shares of common stock.
• Dr. Akkaraju beneficially owns 9.99% of the Issuer's outstanding common stock. Due to field limitations of the EDGAR filing system, the percentage listed in Row 11 of Dr. Akkaraju's cover page has been rounded down to 9.9%.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by investment firms like Samsara BioCapital in biotechnology or pharmaceutical companies are common, especially following equity offerings. This often signals a belief in the company's pipeline or market potential, though the passive nature of a 13G filing suggests a focus on investment return rather than direct operational control.

Stakeholder Impact

• Shareholders: The acquisition of a significant stake by Samsara BioCapital may be viewed positively, suggesting external confidence in the company's value. However, the passive nature of the investment limits immediate impact on corporate control.
• Management: The current management of PMV Pharmaceuticals is not directly addressed in this filing, but the presence of a large passive investor may influence future strategic considerations.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Samsara BioCapital will continue to monitor PMV Pharmaceuticals' performance and market developments.
• The Reporting Persons may adjust their holdings based on future circumstances, subject to the 'Beneficial Ownership Blockers'.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' based on this filing. While the acquisition of a significant stake by Samsara BioCapital suggests potential upside and confidence in PMV Pharmaceuticals, the passive nature of the Schedule 13G filing and the limitations imposed by 'Beneficial Ownership Blockers' indicate that this is primarily an investment position rather than a catalyst for immediate, significant strategic change or control. Investors should await further operational updates or strategic announcements from PMV Pharmaceuticals.

Keywords

PMV Pharmaceuticals, Samsara BioCapital, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Equity Offering